Aruvant’s lead product candidate, ARU-1801, is a potentially curative gene therapy for individuals living with sickle cell disease (SCD) and beta-thalassemia. ARU-1801 is administered once and designed to address the limitations of current curative treatment options, such as low donor availability and chemotherapy conditioning toxicity. ARU-1801 is currently under clinical investigation, and has demonstrated durable, meaningful clinical responses to date for patients with SCD, while only requiring reduced intensity conditioning. ARU-1801 is in an ongoing study that is actively recruiting patients. Click here for more information or email email@example.com.